Design Therapeutics To Present Preclinical Data Highlighting The Potential Of Its GeneTAC Small Molecule, DT-216, For The Treatment Of Friedreich Ataxia At International Congress for Ataxia Research 2022 November 3
Design Therapeutics, Inc. (NASDAQ:DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that preclinical data for the company's novel
